AusCann’s managing director Elaine Darby: “This second harvest in Chile represents an important step in our Chilean operation.
“It is encouraging to see that our medical cannabis can be accessed by patients through the new SAS scheme in Chile whilst clinical studies are progressing.”
Fundación Daya has worked with the Chilean National Institute of Public Health to establish a special access scheme (SAS) which enables patients in Chile access to local medicinal cannabis product.
The medical cannabis product in Chile’s SAS is being locally manufactured at Knop Laboratories from cannabis supplied by DayaCann.
Harvest yielded over 50% more than first crop
The second crop yielded 620 kilograms of dried cannabis product, an increase of over 50% on the 400 kilograms yielded from the first crop.
This equates to a yield of about 1.2 tonnes per hectare.
First-mover following legislative change
AusCann sees the South American market as internationally significant following recent legislative changes in Argentina, which has joined Chile, Colombia and Uruguay in legalising medical cannabis for therapeutic purposes.